INNT
TOTAL INVALIDATION PROCESSED BY THE IB
11/01/2024
Back to search
Official data from USPTO
NAVLIGAR
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
11/01/2024
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
06/30/2016
Registration date
06/20/2017
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/05/2024
Last transaction
01/05/2024
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CH
Examiner
FERRELL, STEVEN
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Novartis AG
Representatives
Novartis Pharma AG, Trademark Department
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Anti-infectives; anti-inflammatories; antibacterial pharmaceutical products; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical products; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical products for ophthalmological use; pharmaceutical products for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and the treatment of allergies; pharmaceutical products for the prevention and treatment of bone diseases; pharmaceutical products for the prevention and treatment of respiratory diseases and asthma
Publications
History of USPTO decisions and trademark events.
18 publications found
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
09/11/2024
INPC
INVALIDATION PROCESSED
09/11/2024
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
09/06/2024
C71T
CANCELLED SECTION 71
01/05/2024
GPNX
NOTIFICATION PROCESSED BY IB
10/13/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
07/27/2017
FIMP
FINAL DISPOSITION PROCESSED
07/27/2017
GPAR
GRANT OF PROTECTION CREATED, TO BE SENT TO IB
07/20/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
06/20/2017
PUBO
PUBLISHED FOR OPPOSITION
04/04/2017
NPUB
NOTICE OF PUBLICATION
03/15/2017
MAFR
APPLICATION FILING RECEIPT MAILED
02/28/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/23/2017
DOCK
ASSIGNED TO EXAMINER
02/22/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/22/2017
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
02/17/2017
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
02/16/2017
Continuous trademark protection
Get notified about every new filing that threatens NAVLIGAR or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.